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Summary  Familial  hypercholesterolaemia  is  an  inherited  disorder,  leading  to  accumulation
of low-density  lipoprotein  (LDL)  particles  in  plasma  and  premature  cardiovascular  disease.
Although  the  phenotype  of  the  rare  homozygous  form  is  always  severe,  the  phenotypic  expres-
sion of  the  common  heterozygous  familial  hypercholesterolaemia  can  vary  considerably.  Beyond
the magnitude  of  the  LDL-cholesterol  elevation  and  the  type  of  mutation,  additional  genetic,
metabolic  and  environmental  cardiovascular  risk  factors  lead  to  the  substantial  variations  in  the
clinical manifestations  and  severity  of  atherosclerotic  disease.  Heterozygous  familial  hypercho-
lesterolaemia  is  often  under-diagnosed  and  under-treated,  and  there  is  an  unmet  need  in  terms
of management  of  severe  heterozygous  forms.  Homozygous  and  severe  heterozygous  familial
hypercholesterolaemia  should  receive  more  intensive  treatment  and  alternative  therapeutic
approaches  are  needed  for  these  high-risk  patients.  In  this  article,  we  review  the  recommen-
dations for  diagnosis  and  treatment  of  severe  familial  hypercholesterolaemia  and  the  agents
currently available  or  under  development.
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Résumé  L’hypercholestérolémie  familiale  est  une  maladie  héréditaire  qui  induit  une  accu-
mulation de  particules  LDL  dans  le  plasma  et  un  risque  accru  de  maladies  cardiovasculaires
précoces.  Alors  que  le  phénotype  de  la  rare  forme  homozygote  est  toujours  sévère,  l’expression
phénotypique  de  la  forme  hétérozygote  fréquente  peut  varier  considérablement.  En  dehors
de l’importance  de  l’élévation  du  LDL-cholestérol  et  du  type  de  mutation,  de  nombreux  fac-
teurs de  risque  cardiovasculaire  additionnels  génétiques,  métaboliques  et  environnementaux
ont un  rôle  important  dans  la  variabilité  des  manifestations  cliniques  et  dans  la  sévérité  de  la
maladie athéromateuse.  Les  hypercholestérolémies  familiales  hétérozygotes  restent  mal  diag-
nostiquées et  insufﬁsamment  traitées  et  il  existe  un  besoin  médical  non  satisfait  en  termes
de prise  en  charge  des  formes  hétérozygotes  sévères.  Les  hypercholestérolémies  familiales
homozygotes  et  hétérozygotes  sévères  doivent  recevoir  un  traitement  plus  intensif  et  de
nouvelles alternatives  thérapeutiques  sont  nécessaires  pour  ces  patients  à  très  haut  risque.
Cet article  est  une  revue  des  recommandations  vis-à-vis  du  diagnostic  et  du  traitement  des
hypercholestérolémies  familiales  sévères,  avec  présentation  des  médicaments  actuellement
disponibles  et  en  développement.
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Background
Autosomal  dominant  familial  hypercholesterolaemia  (FH)
is  among  the  most  common  inherited  disorders  [1].  FH  is
characterized  by  an  elevation  of  low-density  lipoprotein
cholesterol  (LDL-C)  due  to  reduced  uptake  of  plasma  LDL
particles  by  the  liver.  Affected  subjects  are  at  increased
risk  of  all  atherosclerotic  diseases  secondary  to  lifelong  ele-
vations  in  LDL-C.  The  pattern  of  inheritance  is  autosomal
codominant  and  the  main  gene  involved  in  FH  is  the  LDL
receptor  (LDL-R) gene.  However,  mutations  leading  to  FH
have  been  also  described  in  two  other  genes:  apolipoprotein
B  (ApoB) and  proprotein  convertase  subtilisin/kexin  type  9
(PCSK9).  The  vast  majority  of  families  show  only  heterozy-
gous  carriage  of  the  causal  gene.  Homozygotes  or  compound
heterozygotes  are  rare  but  are  characterized  by  very  high
concentrations  of  LDL-C  and  severe  atherosclerosis  during
childhood.  As  a  result,  all  patients  with  homozygous  FH  must
be  classiﬁed  in  the  category  of  severe  hypercholesterolae-
mia.
Although  the  cause  of  FH  is  monogenic,  heterozygous
FH  can  have  widely  different  concentrations  of  LDL-C.
Moreover,  various  additional  environmental  and  metabolic
factors  are  assumed  to  affect  the  clinical  phenotype  of  het-
erozygous  FH.  Major  cardiovascular  risk  factors  in  individuals
with  heterozygous  FH  have  been  identiﬁed  and  several  cate-
gories  of  risk  have  been  proposed  according  to  the  presence
of  these  major  risk  factors  and/or  clinical  atherosclerosis
[2,3].
Despite  the  use  of  currently  available  lipid-lowering
treatments  (LLTs),  a  high  proportion  of  patients  with  severe
forms  of  FH,  including  homozygous  FH  and  severe  het-
erozygous  FH,  do  not  reach  treatment  goals  and  remain
at  increased  risk  of  atherosclerotic  cardiovascular  diseases
(CVDs).  New  therapeutic  approaches  are  crucial  for  these
patients.  There  is  a  need  to  better  deﬁne  the  categories  of
severe  FH  eligible  for  these  new  treatment  options.Diagnosis and cardiovascular risk of FH
FH  is  caused  by  mutations  mainly  in  LDL-R  gene  but  also  in
other  genes  (ApoB, PCSK9, etc.)  [4].  Individuals  with  two
r
s
a
os  droits  réservés.
utations  (homozygous  FH)  are  easy  to  diagnose  due  to  the
everity  of  the  disease.  By  comparison,  many  people  with
he  heterozygous  form  are  undiagnosed  or  are  only  diag-
osed  after  their  ﬁrst  coronary  event.
omozygous FH
omozygous  FH  is  a  very  rare  (1  per  1  million  people)
utosomal  dominant  disease,  usually  caused  by  mutations
n  the  LDL-R  gene  or  other  genes,  leading  to  very  high
lasma  concentrations  of  LDL-C  and  earlier  onset  of  coronary
eart  disease  (CHD)  than  in  subjects  with  heterozygous  FH.
omozygous  FH  patients  are  classiﬁed  into  two  major  groups
ased  on  the  amount  of  LDL-R  activity:  patients  with  less
han  2%  of  normal  LDL-R  activity  are  classiﬁed  as  receptor-
egative  and  patients  with  2  to  25%  of  normal  LDL-R  activity
s  receptor-defective.  In  practice,  children  with  two  het-
rozygous  FH  carrier  parents  have  a  25%  chance  of  inheriting
oth  defective  genes,  leading  to  homozygous  FH  with  either
he  same  genetic  mutation  from  both  parents  or  two  dif-
erent  mutations  from  each  parent  (also  named  compound
eterozygous).
Homozygous  FH  is  characterized  by  extremely  high
oncentrations  of  total  cholesterol  (usually  in  the  range
.0—10.0  g/L)  and  LDL-C.  In  a  large  homozygous  FH
ohort,  the  mean  LDL-C  concentration  for  untreated
ubjects  was  6.15  g/L  [5].  High-density  lipoprotein  choles-
erol  (HDL-C)  concentrations  are  often  decreased  and
riglyceride  (TG)  concentrations  are  usually  normal
5].
In  childhood,  patients  with  homozygous  FH  develop  mul-
iple  types  of  xanthomas,  including  tendinous  and  tuberous
anthomas,  xanthelasmas  and  particularly  cutaneous  planar
anthomas,  being  considered  as  pathognomonic  of  the  dis-
ase  [1].  Accelerated  atherosclerosis  appears  in  childhood
nd  develops  initially  in  the  aortic  root,  causing  valvular  and
upravalvular  aortic  stenosis,  then  extension  into  the  coro-
ary  ostia.  Untreated  patients  with  homozygous  FH  who  are
eceptor-negative  rarely  survive  beyond  the  second  decade;
eceptor-defective  patients  have  a  slightly  better  progno-
is  but,  with  few  exceptions,  develop  clinically  signiﬁcant
therosclerotic  vascular  disease  by  the  age  of  30  years  (and
ften  sooner)  [1,6].
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eterozygous FH
he  prevalence  of  heterozygous  FH  is  1  in  300—500  in  West-
rn  populations,  making  heterozygous  FH  one  of  the  most
ommon  inherited  disorders.  Known  causes  of  heterozygous
H  include  mutations  in  three  major  genes:  the  LDL-R, ApoB
nd  PCSK9  genes  [4,7]. However,  heterozygous  FH  is  most
ommonly  attributable  to  mutations  in  the  LDL-R  gene.  In  a
ecent  French  cohort,  the  respective  contributions  of  each
nown  gene  were  73.9%  for  LDL-R, 6.6%  for  ApoB  and  only
.7%  for  PCSK9  [7].  No  mutation  was  found  in  19%  of  the
robands,  underscoring  the  existence  of  mutations  located
n  still  unknown  genes.
The  clinical  criteria  used  to  identify  patients  with  het-
rozygous  FH  include  high  plasma  concentrations  of  total
holesterol  and  LDL-C,  the  presence  of  tendon  xanthomas  in
he  patient  or  ﬁrst-degree  relative,  a  family  history  of  hyper-
holesterolaemia  (especially  in  children)  and  a  personal
r  family  history  of  premature  CHD  [8].  Usually,  heterozy-
ous  FH  patients  have  LDL-C  concentrations  ranging  from
.9  to  4.0  g/L.  However,  the  range  of  total  cholesterol  and
DL-C  concentrations  in  heterozygous  FH  overlaps  with  con-
entrations  observed  in  polygenic  hypercholesterolaemia.
oreover,  heterozygous  FH  patients  can  have  LDL-C  con-
entrations  less  than  1.90  g/L.  Thus,  additional  criteria  are
eeded  to  conﬁrm  the  diagnosis  of  FH.  TGs  are  usually  in  the
ormal  range  but  some  patients  with  FH  have  elevated  TG
oncentrations  explained  either  by  environmental  factors  or
y  interactions  with  other  genes.  Plasma  concentrations  of
ipoprotein(a)  (Lp[a])  are  also  often  elevated  in  FH  patients.
endon  xanthomas  are  essentially  pathognomonic  of  FH.
owever,  tendon  xanthomas  are  rare  until  the  fourth  decade
f  life.  Additional  sites  of  cholesterol  deposits  are  the  cornea
cornea  arcus)  and  the  eyelids  (xanthelasmas)  but  these  sites
re  not  speciﬁc  for  heterozygous  FH.
a
a
w
a
Table  1  Diagnosis  of  FH:  Simon  Broome  Register  criteria  [2].
A  deﬁnite  diagnosis  of  FH  requires
Cholesterol  concentrations  as  deﬁned  in  this  table  and  tendo
relative
OR
DNA-based  evidence  of  an  LDL-R  mutation,  an  ApoB  mutatio
A  possible  diagnosis  of  FH  requires  cholesterol  concentrations  a
Family  history  of  myocardial  infarction  before  age  50  years  in
ﬁrst-degree  relative
OR
Family  history  of  raised  cholesterol  >  2.9  g/L  (7.5  mmol/L)  in
(6.7  mmol/L)  in  children  aged  <  16  years
Cholesterol  concentrations  to  be  used  as  diagnostic  criteria  for
Total  cholesterol  
Child/young  person  >  2.60  g/L  
(>  6.7  mmol/L)  
Adult  >  2.90  g/L  
(>  7.5  mmol/L)  
ApoB: apolipoprotein B; FH: familial hypercholesterolaemia; LDL-C: lo
PCSK9: proprotein convertase subtilisin/kexin type 9.M.  Farnier,  E.  Bruckert
In practice,  clinical  diagnosis  can  still  be  difﬁcult  due  to
he  variability  of  clinical  expression,  even  among  individ-
als  who  share  the  same  genetic  defect.  By  consequence,
everal  sets  of  criteria  have  been  developed  for  diagnosing
H.  Among  the  best  validated  criteria,  the  Simon  Broome
egister  criteria  (Table  1)  [2]  and  the  Dutch  Lipid  Clinic  Net-
ork  criteria  (Table  2)  [8]  for  FH  are  the  most  widely  used.
sing  these  scores,  a  clinical  diagnosis  of  FH  can  be  made  on
he  basis  of  clinical  characteristics  and  laboratory  ﬁndings.
hen  the  diagnosis  is  uncertain  (possible  or  probable),  the
etection  of  a mutation  in  the  causal  gene  provides  the  only
nequivocal  diagnosis.  Diagnosis  of  heterozygous  FH  using
NA-based  mutation  screening  methods  should  be  proposed
o  decrease  the  rate  of  under-diagnosis.  The  NICE  guide-
ines  state  that  all  patients  with  a  clinical  diagnosis  of  FH
hould  be  offered  a  DNA  diagnostic  test  and  referral  for  fam-
ly  cascade  testing  in  order  to  identify  relatives  affected  [2].
ndeed,  the  most  effective  strategy  for  diagnosing  patients
ith  FH  is  to  screen  close  relatives  of  patients  already  diag-
osed  with  FH  [9,10]. Cascade  screening  involves  testing
ipid  concentrations  in  all  ﬁrst-degree  relatives  of  diagnosed
H  patients.  In  families  where  the  mutation  has  been  iden-
iﬁed,  genetic  testing  should  also  be  included  in  cascade
creening.
Untreated  patients  with  FH  are  at  very  high  risk  of  pre-
ature  CHD  and  death.  Before  statin  treatment,  around  50%
f  men  experienced  cardiovascular  disease  by  the  age  of
0  years  and  around  30%  of  women  by  the  age  of  60  years
2,11].  However,  among  people  with  FH,  the  phenotypic
xpression  in  terms  of  onset  and  severity  of  atherosclerotic
isease  varies  considerably.  The  type  of  genetic  mutation,
s  well  as  other  genetic  factors,  may  contribute  to  this  vari-
bility  [12]. However,  the  risk  differs  even  among  individuals
ho  share  the  same  defect  [12]  and  LDL-C  concentrations
re  a more  important  risk  factor  than  the  type  of  LDL-R
n  xanthomas  in  the  patient  or  in  a ﬁrst-  or  second-degree
n  or  a  PCSK9  mutation
s  deﬁned  in  this  table  and  at  least  one  of  the  following
 a  second-degree  relative  or  before  age  60  years  in  a
 an  adult  ﬁrst-  or  second-degree  relative  or  >  2.6  g/L
 the  index  individual
LDL-C
>  1.55  g/L
(>  4.0  mmol/L)
>  1.90  g/L
(>  4.9  mmol/L)
w-density lipoprotein cholesterol; LDL-R: low-density receptor;
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Table  2  Diagnosis  of  FH:  Dutch  Lipid  Clinic  Network  criteria  [8].
Characteristics  Number
Family  history
First-degree  relative  known  to  have  prematurea CVD  1
First-degree  relative  known  to  have  LDL-C  >  95th  percentile
OR
First-degree  relative  with  tendon  xanthoma  or  arcus  cornealis 2
Children  aged  <  18  years  with  LDL-C  >  95th  percentile
Clinical  history
Patient  has  prematurea CAD  2
Patient  has  prematurea cerebral  or  peripheral  vascular  disease  1
Physical  examination
Tendon  xanthomas 6
Arcus  cornealis  below  age  45  years  4
Laboratory  analysis
LDL-C  >  3.30  g/L  >  8.5  mmol/L  8
LDL-C  2.50—3.29  g/L  6.5—8.4  mmol/L  5
LDL-C  1.90—2.49  g/L  5.0—6.4  mmol/L  3
LDL-C  1.55—1.89  g/L  4.0—4.9  mmol/L  1
DNA  analysis
Functional  mutation  gene  present  8
Diagnosis  of  FH
Certain  when  >  8  points
Probable  when  6—7  points
Possible  when 3—5 points
CVD: cardiovascular disease; CAD: coronary artery disease; FH: familial hypercholesterolaemia; LDL-C: low-density lipoprotein
cholesterol.
a Men aged < 55 years or women aged < 60 years.
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‘mutation  [13]. Additional  atherogenic  risk  factors  play  a
crucial  role  in  the  clinical  expression  of  FH  [14]. Risk  fac-
tors  for  cardiovascular  disease  are  similar  in  individuals  with
or  without  FH.  However,  in  the  setting  of  high  cholesterol
concentrations,  the  effect  of  each  risk  factor  is  ampliﬁed
[3].
In  summary,  the  clinical  prognosis  of  heterozygous  FH
is  related  not  only  to  the  magnitude  of  the  LDL-C  eleva-
tion  and  to  the  longer  duration  of  high  LDL-C  exposure
but  also  to  the  presence  of  other  genetic  or  environmen-
tal  cardiovascular  risk  factors.  Individuals  with  FH  who  are
at  highest  risk,  especially  those  with  the  more  severe  forms
of  FH,  must  be  identiﬁed  and  should  receive  more  intensive
treatment.
Identiﬁcation of severe FH
An  important  step  in  improving  the  management  of  patients
with  severe  FH  is  better  deﬁnition  of  this  patient  subpopula-
tion  that  needs  speciﬁc  therapeutic  options.  Indeed,  despite
the  use  of  currently  available  LLTs,  a  signiﬁcant  proportion  of
patients  with  severe  forms  of  FH,  including  homozygous  FH
and  severe  heterozygous  FH,  do  not  reach  treatment  goals
and  therefore  remain  at  elevated  risk  for  atherosclerotic
CVD.
g
p
3
aUntil  now,  no  clear  deﬁnition  of  severe  heterozygous
H  has  been  proposed  [15]. Recommendations  from  the
ational  Lipid  Association  (NLA)  Expert  Panel  on  FH  have
eﬁned  characteristics  of  FH  patients  at  the  highest  cardio-
ascular  risk  [3]:  established  CHD  or  other  atherosclerotic
VD,  or  the  presence  of  additional  major  risk  factors,  includ-
ng  diabetes,  smoking  and  family  history  of  very  premature
VD  (Table  3),  places  patients  with  heterozygous  FH  in  the
ery-high-risk  category  [3].
Several  other  risk  factors  contribute  to  amplifying  the
isk  in  FH  patients.  The  NLA  recommendations  propose  that
he  presence  of  two  or  more  associated  risk  factors  should
lace  these  patients  in  the  very-high-risk  category  (Table  3).
articularly,  recent  evidence  supports  a  speciﬁc  role  for  high
p(a)  in  the  global  cardiovascular  risk  of  FH  patients  [16].
n  clinical  practice,  all  the  categories  of  patients  listed  in
able  3  should  be  considered  at  very  high  risk,  need  more
ggressive  modiﬁcation  of  lifestyle  and  other  modiﬁable
ardiovascular  risk  factors  and  should  receive  more  inten-
ive  treatment  of  their  hypercholesterolaemia.  Among  these
ery-high-risk  FH  patients,  some  could  be  classiﬁed  as  having
severe  FH’,  including  homozygous  FH  and  severe  heterozy-
ous  FH,  with  severe  heterozygous  FH  clinically  deﬁned  as:
atients  on  maximal  LTT  with  LDL-C  greater  or  equal  to
.0  g/L  and  0—1  risk  factor;  or  LDL-C  greater  or  equal  2.0  g/L
nd  greater  or  equal  2  risk  factors  or  Lp(a)  greater  or  equal
660  M.  Farnier,  E.  Bruckert
Table  3  Higher-risk  FH  patients  (adapted  from  [3]).
Homozygous  FH  patients
Heterozygous  FH  patients  with  any  of  these  very-high-risk  characteristics
Established  CHD  or  other  CVD
Smoker
Diabetes  mellitus
Family  history  of  very-premature-onset  CHD
First-  or  second-degree  male  relative  with  onset  before  age  45  years
First-  or  second-degree  female  relative  with  onset  before  age  55  years
Two  or  more  cardiovascular  risk  factors  among  this  list:
Increasing  age  (men  >  30  years;  women  >  40  years)
LDL-C  >  2.50  g/L
Male  sex
Family  history  of  premature-onset  CHD
First-degree  male  relative  with  onset  before  age  55  years
First-degree  female  relative  with  onset  before  age  65  years
Metabolic  syndrome
HDL-C  <  0.40  g/L
Hypertension  (BP  >  140/90  mmHg  or  drug  treatment)
Lp(a)  ≥  0.50  g/L
Tendon  xanthoma
BP: blood pressure; CHD: coronary heart disease; CVD: cardiovascular disease; FH: familial hypercholesterolaemia; HDL-C: high-density
lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Lp(a): lipoprotein(a).
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t.50  g/L;  or  LDL-C  greater  or  equal  1.6  g/L  and  established
HD  or  other  CVD  or  diabetes.
The  recent  European  Society  of  Cardiology/European
therosclerosis  Society  (ESC/EAS)  guidelines  [17]  and  NLA
ecommendations  [3]  proposed  an  LDL-C  goal  less  than
.0  g/L  (2.5  mmol/L)  [or  less  than  0.7  g/L  (1.8  mmol/L)  in
SC/EAS  guidelines  for  very-high-risk  subjects].  However,
hese  targets  cannot  be  reached  in  patients  with  high  LDL-C
oncentrations.  An  alternative  target  is  to  reduce  LDL-C  con-
entrations  by  greater  or  equal  50%  for  severe  FH.  In  prac-
ice,  the  maximal  reduction  of  LDL-C  should  be  considered
sing  appropriate  drug  combinations  in  tolerated  doses.
urrent treatment options
he  aim  of  treatment  of  FH  patients  is  the  reduction  of
lasma  LDL-C  concentrations  to  decrease  the  risk  of  CVD.
ven  if  lifestyle  modiﬁcations  alone  are  insufﬁcient  to  obtain
esirable  LDL-C  concentrations,  healthy  lifestyle  remains
n  important  aspect  of  FH  treatment,  with  many  beneﬁts
eyond  LDL-C  lowering.  Lifestyle  intervention  comprises  a
ealthy  diet,  reduction  of  excessive  body  weight,  no  smok-
ng  and  moderate  physical  activity  [17]. The  recommended
iet  for  all  FH  patients  includes  reduced  intake  of  saturated
ats  and  cholesterol  (total  fat  25—35%  of  total  calories;  satu-
ated  fat  less  than  7%  of  total  calories;  cholesterol  less  than
00  mg  per  day),  use  of  plant  stanols  or  sterols  (1.5—2  g  per
ay)  and  use  of  soluble  ﬁbres  (10—20  g  per  day)  [18].
All  adults  with  heterozygous  FH  and  children  with  LDL-C
reater  or  equal  1.9  g/L  after  lifestyle  changes  will  require
rug  therapy.  The  current  treatment  options  are  reviewed
or  heterozygous  and  homozygous  FH,  with  a  focus  on  the
nmet  medical  needs.
m
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beterozygous FH
lacebo-controlled  cardiovascular  endpoint  trials  are  uneth-
cal  in  adults  with  a  diagnosis  of  FH  as  these  individuals
re  at  very  high  risk  of  premature  onset  CHD.  Clinical  man-
gement  is  therefore  largely  based  on  extrapolation  from
he  results  of  cholesterol-lowering  trials  done  in  hyperc-
olesterolaemic  patients  [19]. The  current  treatment  steps
or  the  management  of  adults  with  heterozygous  FH  are
isted  in  Table  4:  FH  patients  should  receive  a  potent  statin
mainly  atorvastatin  and  rosuvastatin).  In  a meta-analysis
f  14  randomized  placebo-controlled  trials  of  statin  treat-
ent,  patients  with  baseline  LDL-C  greater  than  1.75  g/L
ad  the  same  relative  risk  reduction  as  those  with  lower  LDL-
 concentrations  [19]. In  a  subsequent  meta-analysis,  high
oses  of  statin  reduced  the  risk  of  CVD  more  than  moder-
te  doses,  regardless  of  baseline  LDL-C  concentration  [20].
oreover,  observational  data  from  two  large  cohorts  of  FH
atients  in  Europe  conﬁrmed  the  efﬁcacy  of  statins  in  het-
rozygous  FH  [21,22]:  in  the  Dutch  cohort  study,  the  risk
f  myocardial  infarction  in  statin-treated  FH  patients  was
ot  signiﬁcantly  greater  than  that  in  an  age-matched  sam-
le  from  the  general  population  [22]. Similarly,  in  the  UK
imon  Broome  register,  asymptomatic  FH  patients  treated
ith  statins  had  reductions  in  all-cause,  cancer  and  coro-
ary  mortality  [21]. All-cause  mortality  was  33%  lower  than
n  the  general  population,  mainly  due  to  a  37%  lower  risk  of
atal  cancer.
Statins  are  generally  safe  and  well  tolerated  [23]. The
otential  adverse  effects  of  statins  in  FH  patients  are  similar
o  those  observed  for  other  patients  receiving  statin  treat-
ent,  particularly  increased  liver  enzymes  and  myopathy.
atients  who  do  not  tolerate  potent  statin  therapy  might
e  offered  another  statin  or  very-low-dose  statin  therapy  in
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Table  4  Current  treatment  steps  for  the  management  of  heterozygous  FH.
First  step  Lifestyle  changes  (including  dietary  adjuncts)  and  moderate-to-high  doses  of  high-potency  statins  to
achieve  LDL-C  goal  <  1.0  g/L  (or  <  0.7  g/L  for  very-high-risk  subjects)  or  LDL  reduction  ≥  50%  from
baseline
Second  step Combination  therapy
Statin  +  ezetimibe  (addition  of  ezetimibe  for  patients  not  at  goal  or  intolerant)
Third  step Triple  therapy
Statin  +  ezetimibe  +  bile  acid  sequestrant
OR
Statin  +  ezetimibe  +  nicotinic  acid
Last  step  LDL  aphaeresis  (for  severe  patients  with  LDL-C  >  2.0  g/L  in  secondary  prevention  or  >  3.0  g/L  in  primary
prevention  on  maximally  tolerated  LLT)
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combination  with  other  LLT.  Low  potency  statins  may  be  less
likely  to  induce  myopathy  but  do  not  enable  achievement
of  the  greater  than  50%  reduction  in  LDL-C  recommended
for  FH  patients  [3].  Alternative  LLT  includes  ezetimibe,  bile
acid  sequestrants  (cholestyramine  or  colesevelam)  or  niacin.
Even  among  patients  who  tolerate  the  maximum  doses  of  the
most  potent  statins,  a  combination  of  one  or  more  non-statin
drugs  is  often  necessary  to  achieve  the  recommended  LDL-C
goals,  particularly  for  the  severe  forms  previously  described.
Given  the  tolerability  and  safety  proﬁle  of  ezetimibe,  it  is
reasonable  to  consider,  as  a  second  treatment  step,  the  addi-
tion  of  ezetimibe  to  a  maximal  dose  of  statin  in  FH  patients
who  require  intensiﬁcation  of  therapy.  A  20  to  30%  comple-
mentary  reduction  in  LDL-C  concentration  is  obtained  with
ezetimibe  but  few  patients  with  severe  heterozygous  FH
reach  the  LDL-C  goal  less  than  1.0  g/L  [24]. The  third  step
is  triple  therapy,  such  as  a  statin  with  ezetimibe  and  bile
acid  sequestrant  or  a  statin  with  ezetimibe  and  niacin;  the
addition  of  colesevelam  to  a  statin  and  ezetimibe  decreased
LDL-C  concentrations  by  12%  [25].
In  the  real  word,  a  large  proportion  of  patients  with  FH
do  not  reach  treatment  goals  and,  by  consequence,  remain
at  increased  risk  of  CVD  [26,27].  For  example,  in  a  recent
large  cross-sectional  study  conducted  in  the  Netherlands,
nearly  all  heterozygous  FH  patients  (96%)  were  on  statin
treatment.  Only  21%  of  patients  achieved  the  LDL-C  goal  less
than  1.0  g/L  (less  than  2.5  mmol/L)  and  about  5%  of  patients
still  had  an  LDL-C  concentration  greater  than  2.0  g/L.  Among
those  not  at  goal,  27%  were  on  combination  therapy  of  max-
imum  statin  dose  and  ezetimibe  [27]. These  data  emphasize
the  need  for  new  LDL-lowering  therapies.  Until  now,  for
patients  with  severe  heterozygous  FH  and  inadequate  LDL-C
reduction,  only  LDL-aphaeresis—an  extracorporeal  system  to
remove  atherogenic  lipoproteins—can  be  proposed  in  addi-
tion  to  LLT.
Homozygous FH
To  retard  the  progression  of  premature  coronary  and/or  aor-
tic  valvular  disease  [28], aggressive  LLT  must  begin  in  early
childhood.  LDL-aphaeresis  is  the  standard  treatment  for
patients  with  homozygous  FH—it  can  lower  LDL-C  and  Lp(a)
concentrations  safely  and  effectively  [29,30].  However,  the
drawbacks  of  aphaeresis  include  limited  availability  in  some
t
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plesterol; LLT: lipid-lowering therapy.
ountries,  high  cost,  procedure  duration  and  the  need  to
aintain  adequate  vascular  access  [30].
Statins  can  lower  LDL-C  concentrations  substantially  in
omozygous  FH  patients  [31,32]  by  decreasing  secretion  of
poB-containing  lipoproteins  in  receptor-negative  FH  and  by
ncreasing  residual  LDL-R  activity  in  receptor-defective  FH.
n  addition,  ezetimibe  induces  a  complementary  reduction
n  LDL-C  concentrations  [33]. By  consequence,  statins  and
zetimibe  are  classically  used  in  patients  treated  with  LDL-
phaeresis  to  obtain  better  achievement  of  LDL-C  goals  [33].
Even  if  the  LDL-lowering  effect  of  treatment  with  a  statin
r  a  statin  plus  ezetimibe  is  less  than  the  effect  usually
bserved  in  heterozygous  FH  patients,  these  LLTs  can  be
ssociated  with  a  signiﬁcant  reduction  in  cardiovascular
orbidity  and  mortality,  as  shown  in  a  recent  retrospec-
ive  study  [5].  This  important  study  was  done  in  a  country
here  few  patients  are  treated  with  LDL-aphaeresis  and  the
revalence  of  homozygous  FH  is  higher:  the  hazard  ratio
or  beneﬁt  from  lipid  therapy  was  0.34  for  the  endpoint
f  death  (P  =  0.02)  and  0.49  for  the  endpoint  of  major  car-
iovascular  events.  This  beneﬁt  occurred  despite  a  mean
eduction  in  LDL-C  of  only  26.4%  with  a  maximal  dose  of  rosu-
astatin  or  atorvastatin  associated  with  ezetimibe  for  half
f  the  patients  [5].  This  study  highlights  the  importance  of
arly  diagnosis  and  initiation  of  LLT  in  young  children  with
omozygous  FH  and  the  need  for  new  therapeutic  options
or  these  very-high-risk  subjects.
uture treatment options
everal  agents  under  development  target  key  steps  in  LDL
etabolism.  Some  other  agents  targeting  HDL  metabolism
ay  also  induce  a  decrease  in  LDL-C  concentrations.  Among
he  emerging  therapeutic  options,  the  most  advanced  is  the
se  of  antisense  oligonucleotides  (ASOs)  to  ApoB100.
ipomersen
argeting  the  ApoB100  protein  seems  an  effective  approach
o  reducing  the  concentrations  of  circulating  atherogenic
ipoproteins,  as  ApoB100  is  required  for  the  synthesis  of
ery-low-density  lipoproteins  (VLDL)  in  the  liver  and  so  the
roduction  of  LDL  particles.  Inhibition  of  the  synthesis  of
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poB100  can  be  achieved  by  blocking  the  translation  of
essenger  ribonucleic  acid  (mRNA)  with  an  ASO  comple-
entary  to  the  mRNA.  Mipomersen  is  a  second-generation
0-mer  phosphorothioate  ASO,  complementary  in  sequence
peciﬁcally  to  a  segment  of  the  human  ApoB100  mRNA.
ipomersen  is  administered  via  subcutaneous  injection
nd  is  predominantly  distributed  to  the  kidney  and  the
iver,  thus  minimizing  potential  inhibition  of  ApoB48  in
he  intestine  [34]. Mipomersen  is  not  metabolized  via
ytochrome  P450  enzymes  involved  in  the  metabolism  of
tatins  and  other  drugs.  Lack  of  interaction  supports  its
se  in  combination  with  oral  LLTs.  As  the  mean  terminal
alf-life  of  mipomersen  is  around  30  days  in  humans  [34], it
as  been  estimated  that  steady  state  will  not  be  achieved
efore  6  months  of  treatment.
The  clinical  efﬁcacy  of  mipomersen  has  been  evaluated
n  several  studies  conducted  in  various  patient  popula-
ions,  including  FH  [35—40]. The  dose  of  200  mg  mipomersen
nce  weekly  was  selected  for  phase  3  trials  and  the  efﬁ-
acy  results  observed  with  this  dose  are  summarized  in
able  5.  Two  phase  3  trials  have  evaluated  the  efﬁcacy  of
ipomersen  in  homozygous  FH  and  severe  heterozygous  FH
atients  on  maximal  tolerated  LTT.  Fifty-one  patients  with
omozygous  FH  not  treated  by  LDL-aphaeresis  were  random-
zed  2:1  to  200  mg  mipomersen  or  placebo  [39]. After  26
eeks  of  treatment,  the  mean  reductions  in  LDL-C  and  ApoB
ere,  respectively,  25%  and  27%  in  the  mipomersen  group
ompared  with  3%  and  3%  in  the  placebo  group  (P  <  0.001).
n  the  second  phase  3  study  [40], 58  high-risk  patients  with
evere  heterozygous  FH  (LDL-C  greater  or  equal  3.0  g/L  or
DL-C  greater  or  equal  2.0  g/L  with  CHD  or  another  form
f  clinical  atherosclerotic  disease,  despite  maximally  toler-
ted  LLT)  were  randomized  2:1  to  200  mg  mipomersen  or
lacebo.  After  26  weeks  of  treatment,  a  mean  reduction  in
DL-C  of  36%  was  observed  in  the  mipomersen  group  versus
n  increase  of  13%  in  the  placebo  group  (P  <  0.001).  Similarly,
ipomersen  produced  signiﬁcant  (P  <  0.001)  reductions  in
ther  atherogenic  lipoproteins  (ApoB:—36%;  Lp(a):—33%).
Common  adverse  events  observed  during  mipomersen
reatment  include  injection  site  reactions,  ﬂu-like  symp-
oms  and  increases  in  alanine  aminotransferase  (ALT).
ore  than  90%  of  patients  experienced  local  injection  site
eactions,  generally  characterized  by  a  painless  transient
rythema  occurring  within  24  hours  after  the  injection.
atients  complained  sometimes  of  pain,  tenderness,  local
welling,  pruritus  and  discoloration  at  the  injection  site.  The
ost  important  long-term  safety  concern  is  directly  related
o  the  mechanism  of  action  of  mipomersen:  the  inhibition
f  ApoB  synthesis  may  induce  an  accumulation  of  TGs  in  the
iver  by  inhibition  of  VLDL  production,  leading  to  an  increase
n  concentrations  of  transaminases  and  hepatic  steatosis.
ith  the  recommended  dose  of  200  mg  per  week,  in  patients
ith  severe  heterozygous  FH  [40], 15%  of  patients  had  per-
istent  ALT  elevations  greater  than  three  times  the  upper
imit  of  normal.  In  homozygous  patients  [39], four  patients
mong  the  34  randomized  to  mipomersen  had  a  signiﬁcant
ncrease  in  ALT  (greater  than  three  times  the  upper  limit  of
ormal)  and  only  one  patient  had  a  signiﬁcant  increase  in
epatic  fat  from  an  abnormal  baseline  of  9.6%  up  to  24.9%,
hich  returned  to  6%  after  stopping  treatment.  ALT  ele-
ations  have  not  been  associated  with  clinically  signiﬁcant
ncreases  in  bilirubin.
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A speciﬁc  study  was  conducted  to  evaluate  the  effect
f  mipomersen  on  intrahepatic  TG  content  using  proton
agnetic  resonance  spectroscopy  [41]. Twenty-one  patients
ith  heterozygous  FH  on  stable  LLT,  TG  less  than  2.0  g/L  and
o  diabetes  mellitus  or  liver  disease,  received  a weekly  sub-
utaneous  injection  of  200  mg  mipomersen  or  placebo  for
3  weeks:  1/10  subjects  in  the  mipomersen  group  devel-
ped  mild  hepatic  steatosis  (intrahepatic  TG  content  of
.7%),  which  resolved  in  the  follow-up.  For  the  whole  group,
here  was  a  non-signiﬁcant  trend  towards  an  increase  in
ntrahepatic  TG  content.  Even  if  this  study  was  reassuring,
imitations  included  the  small  sample  size,  the  exclusion
f  patients  at  increased  risk  of  hepatic  steatosis  and  the
hort  treatment  period.  There  is  still  a need  for  long-term
afety  data  regarding  the  effect  of  mipomersen  on  intra-
epatic  TG  content,  including  patients  with  an  increased
isk  of  hepatic  steatosis,  prior  to  broadening  the  use  of
his  new  strategy.  To  date,  the  indication  of  mipomersen
s  limited  to  patients  with  homozygous  FH  and  patients  with
evere  heterozygous  FH,  as  an  adjunct  to  maximally  toler-
ted  LLT.
TP inhibitors
n  the  liver,  the  assembly  of  lipids  with  the  ApoB100  molecule
s  mediated  by  the  microsomal  triglyceride  transfer  protein
MTP).  Consequently,  MTP  inhibition  could  lead  to  reductions
n  the  secretion  of  atherogenic  lipoproteins  from  the  liver
nd  also  reduce  the  assembly  and  secretion  of  chylomicrons
n  the  intestine.  However,  pharmacological  inhibition  of  MTP
as  resulted  in  signiﬁcant  increases  in  hepatic  steatosis  in
nimals  and  humans.  Few  clinical  data  are  available  for  the
TP  inhibitor  lomitapide  [42,43]: in  a  16-week  open-label
scending-dose  study  conducted  in  six  patients  with  homozy-
ous  FH  receiving  a  low  fat  diet  (less  than  10%  energy  from
at)  to  avoid  potential  steatorrhoea,  lomitapide  was  given
t  increasing  doses  of  0.03,  0.10,  0.30  and  1.0  mg/kg  per
ay  for  4  weeks  [42]. Only  the  doses  of  0.30  and  1.0  mg/kg
educed  LDL-C  signiﬁcantly  (by  25%  and  51%,  respectively)
ith  concomitant  reductions  in  TG  and  ApoB.  Four  patients
ad  elevated  ALT  and  all  patients  had  some  degree  of
epatic  steatosis.  A  second  study  [43]  was  conducted  with
ower  doses  of  lomitapide  (5.0,  7.5  and  10.0  mg  per  day)
n  patients  with  hypercholesterolaemia  and  randomized  to
omitapide  or  ezetimibe  or  lomitapide  plus  ezetimibe  com-
ination  therapy.  Signiﬁcant  reductions  in  ApoB  (24%  with
onotherapy,  37%  with  combination  therapy)  and  non-HDL-
 were  reported;  however  16%  of  the  patients  receiving
omitapide  discontinued  the  drug  due  to  increased  transam-
nase  concentrations.  Gastrointestinal  adverse  effects  were
requent  and  hepatic  steatosis  was  not  evaluated  in  this
hort-term  study.  Increased  intrahepatic  fat  content  remains
 serious  concern  with  this  class  of  drugs  and  long-term
afety  data  are  required.
CSK9 inhibitors
CSK9  is  a  key  regulator  of  LDL  receptor  activity.  Indeed,
ecreted  PCSK9  binds  LDL-R  and  enhances  degradation  of
DL-R  in  the  liver,  thereby  modulating  LDL-C  plasma  con-
entrations  [44]. Loss-of-function  mutations  of  PCSK9  in
umans  are  associated  with  low  concentrations  of  LDL-C  and
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Table  5  Efﬁcacya of  mipomersen  200  mg  per  week  on  plasma  lipid  and  lipoprotein  concentrations.
Study  description  [reference]  LDL-C  (%)  ApoB  (%)  VLDL-C  (%)  Non-HDL-C  (%)  TG  (%)  Lp(a)  (%)
4-week  multiple-dosing  phase  1
study  in  volunteers  with  mild
dyslipidaemia  [38]
−35.2  −38.5  NA  NA  NA  NA
13-week  double-blind
placebo-controlled  phase  2
study  in
hypercholesterolaemic
patients  (monotherapy)  [36]
−45 −46  −53  −44  −46  −42
6-week  double-blind
placebo-controlled  phase  2
study  in  patients  with  heFH
(add-on  therapy)  [37]
−21 −23  −14  −21  −23  −17
13-week  double-blind
placebo-controlled  phase  2
study  in
hypercholesterolaemic
patients  on  stable  statin
therapy  [35]
−35.8  −35.7  −11.0  −28.5  −14.6  NA
26-week  double-blind
placebo-controlled  phase  3
study  in  patients  with  hoFH  on
stable  LLT  [39]
−24.7  −26.8  −17.4  −24.5  −17.4  −31.1
26-week  double-blind
placebo-controlled  phase  3
study  in  patients  with  severe
hypercholesterolaemia  [40]
−36 −36  NA −34 −15  −33
ApoB: apolipoprotein B; HDL-C: high-density lipoprotein cholesterol; heFH: heterozygous familial hypercholesterolaemia; hoFH: homozy-
gous familial hypercholesterolaemia; LDL-C: low-density lipoprotein cholesterol; LLT: lipid-lowering treatment; Lp(a): lipoprotein(a);
NA: not available; TG: triglyceride; VLDL-C: very-low-density lipoprotein cholesterol.
a Efﬁcacy evaluated 14 days post-dosing.
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sprotection  against  CHD  [45]. Inhibition  of  PCSK9  is  emerg-
ing  as  a  very  attractive  new  alternative  for  lowering  LDL-C
concentrations,  particularly  in  combination  with  statins,  as
statin  therapy  can  induce  an  increase  in  PCSK9  expression
[44].  Several  approaches  have  been  described  for  targeting
PCSK9  [46]. The  most  advanced  strategy  is  the  use  of  mono-
clonal  antibodies  against  PCSK9:  a  monoclonal  antibody
can  inhibit  PCSK9  binding  to  LDL-R  and  attenuates  PCSK9-
mediated  reduction  in  LDL-R  protein  concentration.  In
monkeys,  a  single  injection  of  anti-PCSK9  antibody  reduced
LDL-C  by  80%  and  a  signiﬁcant  decrease  was  maintained  for
10  days  [47]. In  humans,  only  data  from  phase  1  trials  and
one  phase  2  trial  are  available.  In  a  multidose  phase  1  study
[48],  subjects  were  treated  with  subcutaneous  injections  of
50  mg,  100  mg  and  150  mg  of  REGN727/SAR236553  antibod-
ies  or  placebo.  A  decrease  in  LDL-C  reaching  around  60%
with  the  100  or  150  mg  doses  was  observed  and  maintained
for  2  weeks.  In  a  recent  phase  2  study  [49], when  added  to
atorvastatin,  REGN727/SAR236553  further  reduced  LDL-C  by
40%  to  72%,  additional  reductions  being  dependent  on  both
the  dose  and  dosing  frequency.  Among  the  candidate  popula-
tions  for  PCSK9  inhibition,  patients  with  severe  heterozygous
FH  are  undoubtedly  a  priority  target.
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he  main  objective  with  this  pharmacological  strategy  is  not
o  lower  LDL-C  but  to  inhibit  the  cholesterol  ester  transfer
rotein  (CETP);  avoiding  the  transfer  of  cholesterol  ester
rom  HDL  to  atherogenic  particles  (VLDL  and  LDL)  can  also
nduce  an  effect  on  the  atherogenic  lipoproteins.  This  effect
as  been  observed  with  anacetrapib:  at  a  dose  of  100  mg  per
ay,  signiﬁcant  reductions  in  LDL-C  (−36%)  and  ApoB  (−18%)
ere  obtained  in  the  DEFINE  study,  concomitantly  with  a
arge  increase  in  HDL-C  (+138%)  [50]. However,  it  remains
o  be  determined  if  CETP  inhibition  is  a  valid  strategy  for
educing  the  incidence  of  cardiovascular  events.
onclusion
atients  with  severe  FH,  including  homozygous  FH  and
evere  heterozygous  FH,  are  at  very  high  risk  of  atheroscle-
otic  diseases.  These  patients  must  be  identiﬁed  early
nd  more  intensive  treatments  are  required,  as  the  drugs
urrently  available  are  insufﬁcient  to  reduce  LDL-C  concen-
rations  to  recommended  targets.  Several  investigational
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gents  under  development  will  provide  new  approaches  to
owering  LDL-C  concentrations  for  these  high-risk  patients.
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